Lercanidipine Hcl Recordati Industria Chimica E Farmaceutica

Lercanidipine hydrochloride, the active ingredient in Lercanidipine HCl Recordati Industria Chimica e Farmaceutica, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering blood pressure.

GNH USA supplies Lercanidipine HCl Recordati Industria Chimica e Farmaceutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium channel blocker used in the management of high blood pressure.

Hypertension: reduces systolic and diastolic blood pressure in adults. Primary hypertension: provides sustained blood‑pressure control for essential hypertension. Isolated systolic hypertension: lowers elevated systolic pressure in older patients.

Lercanidipine may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate pain often occurring after the first dose. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or feet. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Tachycardia: increased heart rate. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Angio‑edema: swelling of face, lips, or throat. - Liver enzyme elevation: significant increase in hepatic transaminases. - Allergic reactions: rash, itching, or hives. - Cardiac conduction disturbances: heart block or arrhythmias.

Before initiating therapy, consider the following safety measures.

Monitor blood pressure regularly: ensure therapeutic effect and avoid excessive lowering. Caution in hepatic impairment: dose adjustment may be required. Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. Use with caution in the elderly: increased sensitivity to hypotensive effects. Contraindicated in severe aortic stenosis: risk of precipitating cardiac failure. Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Concomitant use with other antihypertensives: risk of excessive hypotension. - Grapefruit juice: can elevate drug concentration.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - Diuretics: may enhance electrolyte disturbances. - Beta‑blockers: can mask tachycardia caused by hypotension. - NSAIDs: may blunt antihypertensive effect. - Lithium: possible increase in serum lithium levels.